China's Covid-19 vaccine is safe, prompts antibody response: Lancet | WeForNews | Latest News, Blogs China’s Covid-19 vaccine is safe, prompts antibody response: Lancet – WeForNews | Latest News, Blogs
Connect with us

Published

on

Beijing, Oct 16 : Chinese Covid-19 vaccine candidate — BBIBP-CorV — that is expected to completely inactivate the SARS-CoV-2 virus, is safe and elicits an antibody response, a study published in The Lancet has found.

A previous clinical trial reported similar results for a different vaccine that is also based on inactivated whole SARS-CoV-2 virus, but in that study the vaccine was only tested on people aged under 60 years.

The latest study reported in The Lancet Infectious Diseases journal included participants aged between 18 and 80 years, and found that antibody responses were induced in all recipients.

Participants aged 60 and over were slower to respond, taking 42 days before antibodies were detected in all recipients compared with 28 days for participants aged 18-59.

“Protecting older people is a key aim of a successful Covid-19 vaccine as this age group is at greater risk of severe illness from the disease,” said study author Xiaoming Yang from the Beijing Institute of Biological Products Company Limited in China.

However, vaccines are sometimes less effective in this group because the immune system weakens with age.

“It is therefore encouraging to see that BBIBP-CorV induces antibody responses in people aged 60 and older, and we believe this justifies further investigation,” Yang added.

The BBIBP-CorV vaccine used in the study reported here is based on a sample of the virus that was isolated from a patient in China.

Stocks of the virus were grown in the lab using cell lines and then inactivated using a chemical called beta-proprionolactone.

BBIBP-CorV includes the killed virus mixed with another component, aluminium hydroxide, which is called an adjuvant because it is known to boost immune responses.

The first phase of the study was designed to find the optimal safe dose for BBIBP-CorV.

It involved 96 healthy volunteers aged between 18 and 59 years and a second group of 96 participants aged between 60 years and 80 years.

Within each group, the vaccine was tested at three different dose levels, with two vaccinations administered on day zero and 28.

A fourth group within each age group (24 participants in each age group) were given two doses of a placebo vaccine. In total, in phase 1 of the study, 144 participants received the vaccine and 48 received the placebo.

The second phase of the study was designed to identify the optimal timing schedule for vaccination.

Participants were asked to report any adverse events for the first seven days after each vaccination and these were verified by the research team.

“No serious adverse events were reported within 28 days of the final vaccination. There were no instances of clinically significant changes in organ functions detected in laboratory tests in any of the groups,” the authors wrote.

Health

Researchers identify new drug to treat COVID-19 patients

In the continuing fight against the novel Coronavirus, researchers have now identified a drug with the potential to provide treatment for COVID-19 close to a year after it turned into a pandemic

Published

on

By

Coronavirus News

In the continuing fight against the novel Coronavirus, researchers have now identified a drug with the potential to provide treatment for COVID-19 close to a year after it turned into a pandemic.

The study, published in the journal Cells, found that the approved protease inhibitor aprotinin displayed activity against SARS-CoV-2, the coronavirus that causes COVID-19, in concentrations that are achieved in patients.

According to the researchers, aprotinin aerosols are approved in Russia for the treatment of influenza and could be readily tested for the treatment of COVID-19.

Aprotinin inhibits the entry of SARS-CoV-2 into host cells and may compensate for the loss of host cell protease inhibitors that are downregulated upon SARS-CoV-2 infection.

“The aprotinin aerosol has been reported to be tolerated extremely well in influenza patients. Hence, it may have a particular potential to prevent severe COVID-19 disease when applied early after diagnosis,” said study author Martin Michaelis from the University of Kent in the UK.

“Aprotinin has previously been shown to inhibit TMPRSS2 gene and has been suggested as a treatment option for influenza viruses and coronaviruses. Herein, we investigated the effects of aprotinin against SARS-CoV-2,” Michaelis added.

The findings showed that aprotinin displayed anti-SARS-CoV-2 activity in different cell types (Caco2, Calu-3, and primary bronchial epithelial cell air-liquid interface cultures) and against four virus isolates.

“An approved aprotinin aerosol may have the potential for the early local control of SARS-CoV-2 replication and the prevention of COVID-19 progression to a severe, systemic disease,” the study authors noted.

Continue Reading

Health

No dengue death in Delhi this year

Delhi govt announced zero death in the national capital due to dengue this year so far, giving credit to CM Kejriwal’s campaign against the mosquito-borne tropical disease caused by the dengue virus

Published

on

By

Arvind Kejriwal

Delhi government on Saturday announced zero death in the national capital due to dengue this year so far, giving credit to Chief Minister Arvind Kejriwal’s campaign against the mosquito-borne tropical disease caused by the dengue virus.

The announcement comes as it is going to organise the ninth week of ’10 Hafte 10 Baje, 10 Minute’ anti-dengue campaign on Sunday with Delhi Chief Minister Arvind Kejriwal appealing the citizen to join the movement.

“This is the second last week of the campaign and due to the aggressive campaign by the Delhi government this year no dengue-related death has been reported in the national capital,” the government said in a statement.

This week Delhi Health Minister Satyendar Jain also informed that no dengue-related death has been reported in the national capital this year and credited Kejriwal government’s anti-dengue campaign for this.

“Delhi people did it! No death due to dengue this year. There is also a sharp fall in number of cases compared to figures reported last year. Chief Minister Arvind Kejriwal’s campaign — ’10 hafte 10 baje 10 minute’ — has been made a success by you all,” Jain had tweeted.

As per the Delhi government statement, the Delhi model of fighting dengue is getting applauded across the country and Bollywood actor Amitabh Bachchan recently asked a question about the campaign to a contestant by playing a voice clip of the Delhi Chief Minister in the popular television show KBC.

Delhi Chief Minister Kejriwal earlier had urged citizens here for their collective efforts against the disease, saying “we have to stop the breeding of dengue mosquitoes and protect our family and the entire Delhi from Dengue.”

Kejriwal on last Sunday had also declared that dengue was “under control” in the national capital like previous year.

Last week, the anti-dengue campaign of the Delhi government got support from celebrities such as Shankar Mahadevan, who encouraged the citizens of Delhi to religiously follow the dengue prevention guidelines such as inspecting their residences for signs of stagnant water, draining the accumulated water or adding a layer of oil or petrol to it to prevent the breeding of mosquitoes.

The Delhi government this year launched a Dengue helpline — 01123300012 — and a WhatsApp helpline — 8595920530 — to assist the general public.

Continue Reading

Health

Sero Survey In Bhubaneswar: 50% Residents Develop Antibodies To Fight Coronavirus

Published

on

By

Coronavirus outbreak

Bhubaneswar: Half of the residents of Bhubaneswar have developed antibodies to fight novel Coronavirus. The statistics were revealed by ICMR – Regional Medical Research Centre (RMRC) Director, Dr Sanghamitra Pati today. Dr Pati said the survey was carried out between October 16 and 18 during which 1,400 samples were taken from all wards of Bhubaneswar Municipal Corporation (BMC).

As per the results, 50 per cent of Bhubaneswar’s population have been exposed to COVID-19, which means these many number of people now have the antibodies against the viral disease. “The results of the third sero survey corresponds to the status of infection, at least three weeks prior. So, there is much likelihood that exposure of people here to COVID-19 would have increased by now (October-end),” she said.

The good news is that 90 per cent of the people who are exposed to COVID-19 have very less or no symptoms. This implies that their immune system has been successful in fighting novel Coronavirus. Besides, 30 per cent of the people whose samples were collected have been tested through Rapid Antigen or RT-PCR, said Dr Pati.

Only around 2 per cent of Bhubaneswar’s population was found to be exposed to COVID-19 in the first sero survey. In the second survey in the last week of August, 5.1 per cent of the city’s population was exposed. Now, the result of the third sero survey is very encouraging, she said.

Continue Reading
Advertisement

Most Popular

Corona Virus (COVID-19) Live Data

COVID-19 affects different people in different ways. Most infected people will develop mild to moderate illness and recover without hospitalization.